Depo-Provera Lawsuit: Brain Tumor Claims & Updates

Depo-Provera lawsuits allege that manufacturer Pfizer failed to warn users about an increased risk of developing meningioma brain tumors. As of June 2026, more than 5,000 lawsuits are pending in federal court.

Both sides recently agreed in principle to a global settlement for the Depo-Provera lawsuits that could resolve thousands of cases. Attorneys are still accepting new Depo-Provera cases and you or a loved one may be eligible. A free legal consultation through Drugwatch can help you determine your next steps.

Lawsuit Qualifications

• Diagnosis: Image-confirmed diagnosis of a cranial or spinal meningioma after taking Depo-Provera, Depo-SubQ Provera or an approved generic version of the injection at least twice.
• Timeline: File a claim within the statute of limitations, which may be as little as one year. Contact Drugwatch today to see if you’re still eligible in your state.
• Evidence: A lawyer can help you gather key documents like receipts, imaging reports and doctors’ notes.

People are filing Depo-Provera lawsuits because they developed meningiomas after using the birth control shot. They claim Pfizer failed to adequately warn patients and doctors about that risk. These cases also claim the drug was defectively designed because it can cause meningioma.

Pfizer argued that it could not have added a warning because the FDA rejected its 2024 proposal to add a label. They claim each Depo-Provera lawsuit is preempted by federal law. The agency ultimately approved a label change for meningioma risk in December 2025 based in part on a 2024 BMJ study. The study found that women with long-term Depo-Provera use had 5.6 times greater odds of intracranial meningioma.

Legal Issues and Arguments

Depo-Provera lawsuits focus on what Pfizer knew and how quickly patients were warned. Plaintiffs argue that research connecting Depo-Provera’s active ingredient to meningiomas was available long before U.S. patients were told. For several years, Canada, the EU and other countries have provided clearer warnings about this risk. Now, the FDA officially requires a meningioma warning on Depo-Provera’s label, which supports claims that U.S. patients should have been warned sooner.

Another important issue is Pfizer’s claim that it could not update the warning label without FDA permission. However, FDA rules allow drug companies to use a process called “Changes Being Effected,” or CBE, to add safety warnings as soon as new risks are found, even before the FDA formally approves the change.

If plaintiffs can show that Pfizer had evidence of a meningioma risk but did not act on it, this could weaken the company’s defense. For patients, the main concern is whether important safety information was delayed, which may have limited their ability to make fully informed decisions about their health.

Drugwatch is currently offering free case reviews for women who developed meningioma after taking the Depo-Provera shot. With a global settlement now in the process of being finalized, you can find out if you are eligible to receive compensation.

In June 2026, both sides reached a tentative agreement for a global Depo-Provera settlement. This is a key development for these cases that could bring resolution to much of the litigation. The deal still needs to be finalized.

The first bellwether trial was scheduled for December 2026, but that trial was removed from the schedule following news of a settlement. So far, no details were released regarding potential payout amounts or how many cases will be eligible.

The judge is allowing some procedural parts of the litigation to continue while the settlement is finalized since the agreement is not expected to resolve all cases that have been filed in federal court.

For a comprehensive breakdown of lawsuit and settlement updates, visit our Depo-Provera litigation timeline.

While few details have been released, factors that could affect individual case value include the severity of the meningioma, whether surgery is required, the duration and amount of Depo-Provera use, plaintiff’s age at diagnosis, medical costs, lost wages and any impact on quality of life.

The cases that resulted in the most severe impact on a plaintiff’s life and have the strongest evidence could earn larger payouts.

The primary injury in Depo-Provera brain tumor lawsuits is meningioma. It’s a tumor that starts in the meninges, the thin layers of tissue that cover the brain and spinal cord.

Meningiomas don’t form directly in brain tissue, but they’re often considered brain tumors or spinal cord tumors depending on which organ they form closer to. They grow slowly and may not cause symptoms for years. However, if they get big enough, they can cause more serious problems.

Symptoms listed in the lawsuits include seizures, lightheadedness, weakness, difficulty speaking, ear itching, headaches, dizziness, blurred vision and even death.

One of the first studies to link Depo-Provera to meningioma was the 2024 BMJ study that found women who used Depo could be upwards of five times more likely to develop a meningioma.

Pfizer continues to stand by Depo-Provera’s safety, even after the FDA approved a label warning for meningioma in December 2025. The updated label could strengthen plaintiffs’ arguments that the drug increases the risk of meningioma and that it was possible to add a warning sooner.

Women Who Have Filed Depo-Provera Lawsuits

T.C received Depo-Provera shots for three years and was diagnosed with a meningioma brain tumor. She said she lives in a constant state of worry that the tumor might grow. “I was told how great Depo-Provera was, and I thought it would be more reliable and convenient since I wouldn’t have to take it daily,” she said. “I had no idea it would lead to such serious health problems.” After learning that other people were filing lawsuits, T.C. had her case reviewed and filed a lawsuit in hopes of holding manufacturers accountable.

Edie R. started Depo shots decades ago to help manage scar tissue that formed inside her uterus. She suffered from meningioma symptoms and constant seizures. While she had a craniotomy to remove her tumor, nearly every other symptom that she had worsened after the procedure. “I had to quit my job. I couldn’t do it anymore,” she said. “The financial devastation has been enormous in lost earnings.”

Thousands of women across the country are seeking justice. While these lawsuits can’t undo the harm and hardships that a meningioma diagnosis has on their mental, physical and emotional health, their cases may help recover financial losses and promote positive change for other women.

Filing a Depo-Provera lawsuit starts with a free case evaluation from Drugwatch. When you reach out to Drugwatch, we’ll ask a few questions about your experience using Depo-Provera and your meningioma diagnosis and explain your legal options. Whether or not you have a case depends on certain qualification criteria, and only a lawyer can determine if you qualify.

Eligibility may also depend on how long ago you were diagnosed. Each state has a different deadline for filing. Our attorneys can help you gather records to prove your case.

How To Determine If You Have a Case

• Medical Diagnosis: Confirm a connection between the drug and your health issues.
• Legal Consultation: Speak with a product liability lawyer to review your case and understand your legal options.
• Documentation: Gather prescriptions, treatment notes and all relevant medical records to support your claim.

“If you’ve been diagnosed with a meningioma after using Depo-Provera or Depo-SubQ Provera or their generic equivalents, you may qualify for a lawsuit,” said attorney Brendan Smith, a partner at Simmons Hanly Conroy in the Complex Litigation Department. “Consulting a qualified attorney can help determine if your case meets the specific legal and medical requirements for filing a claim.”